Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17690435 | 1.00 | KDM4C (0.39) | KDM4CDPP4TAAR1ALDH1A1MAPT | |
| SCHEMBL20965466 | 0.82 | DPP4 (0.39) | DPP4TAAR1SLC15A1XIAPDPP8 | |
| SCHEMBL12285504 | 0.82 | DPP4 (0.39) | KDM4CDPP4TAAR1ALDH1A1MAPT | |
| SCHEMBL9911469 | 0.81 | KDM4C (0.42) | KDM4CALDH1A1MAPTTSHRPOLB | |
| SCHEMBL30811127 | 0.81 | KDM4C (0.36) | KDM4CDPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL30811141 | 0.80 | DPP4 (0.44) | KDM4CDPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL24543407 | 0.78 | DPP4 (0.43) | DPP4TAAR1ALDH1A1MAPTPTGS1 | |
| SCHEMBL13164141 | 0.78 | DPP4 (0.43) | DPP4TAAR1ALDH1A1MAPTPTGS1 | |
| SCHEMBL12234218 | 0.78 | DPP4 (0.43) | DPP4TAAR1ALDH1A1MAPTPTGS1 | |
| SCHEMBL29981834 | 0.78 | SLC7A5 (0.50) | KDM4CDPP4SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2335716-A2 | Pancreatic polypeptide family motifs and polypeptides comprising the same | Amylin Pharmaceuticals Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| EP-2335715-A2 | Pancreatic polypeptide family motifs and polypeptides comprising the same | Amylin Pharmaceuticals Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| EP-1789440-A4 | PANCREATIC POLYPEPTIDE FAMILY MOTIFS AND POLYPEPTIDES COMPRISING THE SAME | AMYLIN PHARMACEUTICALS INC (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1789440-A2 | PANCREATIC POLYPEPTIDE FAMILY MOTIFS AND POLYPEPTIDES COMPRISING THE SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-05-30 | — | — | EP | claimed |
| US-20060094653-A1 | Pancreatic polypeptide family motifs and polypeptides comprising the same | ASTRAZENECA PHARMACEUTICALS LP | 2006-05-04 | — | — | US | claimed |
| WO-2005077094-A9 | PANCREATIC POLYPEPTIDE FAMILY MOTIFS AND POLYPEPTIDES COMPRISING THE SAME | AMYLIN PHARMACEUTICALS INC (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2005077094-A2 | PANCREATIC POLYPEPTIDE FAMILY MOTIFS AND POLYPEPTIDES COMPRISING THE SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | WO | claimed |
| EP-4554959-A2 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Pep2Tango Therapeutics Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4533928-A1 | A METHOD FOR CONTROLLING A WORK FUNCTION OF AT LEAST ONE SURFACE, ELECTRODE, ELECTROCHEMICAL CELL ENERGY STORAGE DEVICE, PHOTOVOLTAIC CELL AND ELECTRICAL COMPONENT THEREOF | Chiral Ltd (IL) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384892-A | Method for controlling work function of at least one surface, electrode, electrochemical cell, energy storage device, photovoltaic cell and electrical component thereof | 凯瑞尔有限公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4370537-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Pep2Tango Therapeutics Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240059753-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024015922-A2 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4172365-A1 | COMPOSITIONS AND METHODS FOR SEQUENCING USING AT LEAST ELECTRICAL CHARACTERISTICS | Illumina, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-115843316-A | Compositions and methods for sequencing using at least electrical properties | 伊鲁米纳公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2023288313-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11437501-B2 | Device for electric field induced local magnetization | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-09-06 | — | — | US | disclosed |
| EP-2335716-A2 | Pancreatic polypeptide family motifs and polypeptides comprising the same | Amylin Pharmaceuticals Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2335715-A2 | Pancreatic polypeptide family motifs and polypeptides comprising the same | Amylin Pharmaceuticals Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | KDM4C 4801/4885DPP4 303/4885TAAR1 1261/4885 |
| US-20240059753-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | KDM4C 4801/4885DPP4 303/4885TAAR1 1261/4885 |
| US-20060094653-A1 | Pancreatic polypeptide family motifs and polypeptides comprising the same | GIPR, IAPP, VIP | KDM4C 3810/4885DPP4 136/4885TAAR1 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.